Anavex Life Sciences Corp (AVXL)

[TempePhil]

Whats interesting about the patent is that it gives lists of genes associated with neurodegenerative diseases that they suspect will be of interest. Because the Alz P2a trial was small, Anavex cannot conclusively rule in/out any genes on the lists.
However, you can bet they are KEMing the 509 patient's data in the P2/3 trial against these genes, and probably all trials going forward (at least CNS).